B Group, Inc.

In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), B Group, Inc. reported 18 stock positions worth $176.2 million. Its top holding was Adma Biologics (ADMA) at 15.5% of the portfolio, followed by Palisade Bio (PALI, 13.5%) and NRX Pharmaceuticals (NRXP, 9.5%). Compared with Q1 2026, it opened 1 new position, sold out of 3, added to 5 and reduced 1. The biggest buy was a new position in Faeth Therapeutics (FTH) and the biggest sale an exit from Apogee Therapeutics (APGE).

Most Recent 13F
Q2 2026
Location
DALLAS, TX
CIK
0002043476
Portfolio Value
$176.2M (Q2 2026)
SEC Filing
0001420506-26-001657 ↗ filed Aug 14, 2026

Holdings Value

0$50.0M$100.0M$150.0M$200.0M Q4 2024: $163.6M Q4 2024 Q1 2025: $115.1M Q1 2025 Q2 2025: $115.8M Q2 2025 Q3 2025: $100.1M Q3 2025 Q4 2025: $134.9M Q4 2025 Q1 2026: $134.9M Q1 2026 Q2 2026: $176.2M $176.2M Q2 2026

Holdings 18 stocks · $176.2M
ADMA Adma Biologics Inc. 15.50% 3,262,542 $27.3M Add +1.7%
PALI Palisade Bio Inc. 13.54% 11,414,285 $23.9M No change
NRXP NRX Pharmaceuticals Inc. 9.50% 4,091,767 $16.7M Add +36.4%
FTH Faeth Therapeutics Inc. 8.66% 610,169 $15.3M New
TSHA Taysha Gene Therapies Inc. 6.96% 1,800,556 $12.3M No change
PRAX Praxis Precision Medicines I 6.32% 33,237 $11.1M No change
CLLS Cellectis - ADR 5.59% 3,281,501 $9.8M No change
ZLAB Zai Lab Ltd.-ADR 4.86% 450,646 $8.6M No change
GPCR Structure Therapeutics Inc. 4.26% 140,000 $7.5M Add +9.8%
ORKA Oruka Therapeutics Inc. 4.05% 75,000 $7.1M No change
IOVA Iovance Biotherapeutics Inc. 3.54% 1,500,000 $6.2M No change
SYRE Spyre Therapeutics Inc. 3.53% 70,000 $6.2M Reduce -30.0%
AURA Aura Biosciences Inc. 3.08% 764,243 $5.4M Add +27.9%
ASMB Assembly Biosciences Inc. 2.74% 175,706 $4.8M No change
DRUG Bright Minds Biosciences Inc. 2.69% 67,500 $4.7M No change
RARE Ultragenyx Pharmaceutical Inc. 2.56% 135,000 $4.5M No change
SGHT Sight Sciences Inc. 2.08% 970,000 $3.7M No change
FHTX Foghorn Therapeutics Inc. 0.55% 200,000 $976K Add +96.1%

Options reported separately and not counted above: INVESCO QQQ TR puts ($36.8M).

Portfolio Sells Q1 2026 → Q2 2026
APGE Apogee Therapeutics Inc. Sold out 0.00% −0.47
SYRE Spyre Therapeutics Inc. Reduce -30.0% 3.53% −0.21
SLNO Soleno Therapeutics Inc. Sold out 0.00% −0.19
REPL Replimune Group Inc. Sold out 0.00% −0.15

Portfolio Buys Q1 2026 → Q2 2026
FTH Faeth Therapeutics Inc. New 8.66% +8.66
NRXP NRX Pharmaceuticals Inc. Add +36.4% 9.50% +4.76
FHTX Foghorn Therapeutics Inc. Add +96.1% 0.55% +0.19
AURA Aura Biosciences Inc. Add +27.9% 3.08% +0.12
GPCR Structure Therapeutics Inc. Add +9.8% 4.26% −0.29
ADMA Adma Biologics Inc. Add +1.7% 15.50% −5.93

Options Activity Q1 2026 → Q2 2026
INVESCO QQQ TR put New 50,000 $36.8M

Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 18$176.2MADMA, PALI, NRXP, FTH, TSHA
Q1 2026 20$134.9MADMA, PALI, PRAX, CLLS, ZLAB
Q4 2025 15$134.9MADMA, CLLS, PALI, TSHA, PRAX
Q3 2025 16$100.1MADMA, ZLAB, AKRO, CLLS, TSHA
Q2 2025 15$115.8MADMA, INSM, ZLAB, AKRO, CLLS
Q1 2025 17$115.1MADMA, INSM, ZLAB, AKRO, IOVA
Q4 2024 18$163.6MINVESCO QQQ TR, ADMA, INSM, ZLAB, IOVA